🔗 Share this article

While the US proceeds with historic changes to its vaccine recommendations, an unexpected name appears unexpectedly: Høeg, a Danish American physician and public health researcher who first made her name by questioning COVID-19 vaccinations throughout the global health crisis and has concentrated on possible deaths after Covid immunization in her short position at the Food and Drug Administration.

Proposed Shifts to Pediatric Immunization Program

Health officials were set to reveal sweeping revisions to the pediatric vaccination calendar in December, synchronizing the US with Denmark’s immunization schedule, according to reports – a substantial departure that would put the US out of alignment with a large portion of the global community with insufficient data for improved outcomes. This reveal has been pushed back until the coming year.

Rather than the director of the vaccine center, Tracy Beth Høeg is listed to present at the meeting. She was just designated interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to lead the center this year.

A New Direction at the Agency

Høeg's temporary position might represent a strengthened alliance between the pharmaceutical and vaccine divisions as Høeg and Dr. Prasad strengthen their influence at the FDA – and it signals a increased emphasis upon dismantling already-approved vaccines at the FDA.

The new acting director has frequently advocated for discontinuing specific childhood shot schedules in the US so as to align more like Denmark's approach, a society with nationalized medicine and a population approximately the size of Wisconsin’s.

In her initial statements, she has continued to focus on immunizations – usually the domain of Dr. Prasad, director of the FDA’s vaccine center – rather than drug regulation.

Concerns Over Expertise

Høeg has no obvious background in pharmaceutical research, approval processes or management, which has been typical for past heads of the biologics center. She has worked at the FDA as a top consultant to the FDA chief and the vaccine center since March.

“She doesn’t seem to have the requisite experience” for leading the pharmaceutical oversight division, remarked a neurologist and psychiatrist. “She has not conducted a randomized controlled trial. She lacks experience in running a large organization. She is not an expert in drug approvals.”

Former directors of the center would “grasp regulatory frameworks and the science of pharmaceutical innovation”, commented Janet Woodcock. “Frankly, she doesn’t have the type of experience that previous people who headed CBER have had.”

This division has an enormous workload at the FDA, she emphasized.

“The public just focuses on the novel medication approvals, but the generic program clears a multitude of off-brand pharmaceuticals. There is also a biosimilars program, non-prescription drug unit and other areas, and each of these must be supervised,” Dr. Woodcock said. “The thing you neglect, that is the part that I always told people is going to bite you.”

Furthermore, a substantial administrative aspect to the job, which supervises in excess of 5,000 employees. “It is a massive administrative position, if you execute it properly,” the former official added.

Agency Reaction and Controversial Policies

When asked about questions about Dr. Høeg's qualifications and whether this assignment represents increased cooperation among regulatory chiefs on vaccines, a press secretary said that the “inquiries are based on inaccurate assumptions”.

“Her experience aligns with the functions of her role,” the representative explained, noting the months Dr. Høeg spent counseling the FDA commissioner on “drug safety and oversight research, including computational safety modeling and shot safety tracking”.

In her interim role, Dr. Høeg assumes responsibility for the agency head's controversial expedited review system, a controversial one-day drug-approval program that apparently troubled her former heads. “By what process are these therapies being picked for this expedited pathway? Who takes the decisions?” Howard asked. “There is a lot of lack of transparency happening at the FDA right now.”

Broadly speaking, he stated, “the agency seems to be moving towards laxer regulations of most medications, except for shots.”

Documented Past Work on Vaccines

With vaccines, Høeg has a more established, if concerning, past, Howard observe. She released a analysis using non-validated public submissions to determine the rate of myocarditis after Covid immunization. She counseled the Florida top health official Dr. Joseph Ladapo, who allegedly have changed statistics to indicate Covid vaccinations are more dangerous than they are.

Included in her “wish list” for the incoming federal leadership featured altering guidelines for recently developed shots and ending “optional” immunizations, she said following the vote on a podcast. At the FDA, Høeg has allegedly floated the idea of preventing young men from getting COVID-19 vaccines.

“She’s an complete dogmatist who commences with her preconceived notions and tailors the evidence to accommodate the evidence in a highly disingenuous, dishonest manner,” Howard stated.

Taking Control and a “Push for Payback”

Dr. Høeg aligned with other skeptics, {like|